Cynata is pleased to inform investors that, following the engagement of Japan- based investor relations firm Finantec Co., Ltd. (as announced on the 9th of August 2017), a series of investor briefings will be conducted in Japan this week to further raise awareness among the Japanese investor community.
Cynata’s MD and CEO, Dr Ross Macdonald, recently presented on Cynata at the "Cell and Gene Meeting on the Mesa 2017
Cynata’s unique Cymerus™ mesenchymal stem cell technology is profiled in a new article on platform technologies in the new issue of industry publication Drug Development & Delivery
Please view our presentation at the 19th Annual Rodman & Renshaw Global Investment Conference
Ross Macdonald tells CNBC about how the company has progressed to a phase 1 clinical trial